Longeveron Announces Achievement Of Surpassing 50% Enrollment Threshold In Phase 2 ELPIS II Study Of Lomecel-BTM In Hypoplastic Left Heart Syndrome
Portfolio Pulse from Happy Mohamed
Longeveron Inc. (NASDAQ:LGVN) has announced that it has surpassed the 50% enrollment threshold in its Phase 2 ELPIS II trial of Lomecel-BTM in Hypoplastic Left Heart Syndrome (HLHS). The trial is funded by the National Heart, Lung, and Blood Institute (NHLBI) and uses Longeveron's Lomecel-BTM asset. The company has also activated an additional clinical site to expedite the completion of the trial enrollment. A webinar discussing the unmet medical need and current standard of care for HLHS patients, as well as the potential of Lomecel-BTM, will be held on August 16, 2023.
August 11, 2023 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Longeveron's surpassing of the 50% enrollment threshold in its Phase 2 ELPIS II trial and activation of an additional clinical site could potentially expedite the trial's completion, which may positively impact the company's stock in the short term.
The progress in the trial and the activation of an additional clinical site indicate that the company is on track with its development plans. This could potentially lead to positive outcomes from the trial, which would likely be viewed favorably by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100